120 related articles for article (PubMed ID: 29023715)
21. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
22. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
Mebarki M; Bennaceur A; Bonhomme-Faivre L
Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
24. Organoid development in cancer genome discovery.
Gao D; Chen Y
Curr Opin Genet Dev; 2015 Feb; 30():42-8. PubMed ID: 25796043
[TBL] [Abstract][Full Text] [Related]
25. NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model.
Liu WQ; Lepelletier Y; Montès M; Borriello L; Jarray R; Grépin R; Leforban B; Loukaci A; Benhida R; Hermine O; Dufour S; Pagès G; Garbay C; Raynaud F; Hadj-Slimane R; Demange L
Cancer Lett; 2018 Feb; 414():88-98. PubMed ID: 29111348
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, biological evaluation and molecular modeling studies of 1-aryl-6-(3,4,5-trimethoxyphenyl)-3(Z)-hexen-1,5-diynes as a new class of potent antitumor agents.
Lo YH; Lin YT; Liu YP; Duh TH; Lu PJ; Wu MJ
Eur J Med Chem; 2013 Apr; 62():526-33. PubMed ID: 23419737
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids.
Bulin AL; Broekgaarden M; Hasan T
Sci Rep; 2017 Nov; 7(1):16645. PubMed ID: 29192263
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.
Gil-Ad I; Zolokov A; Lomnitski L; Taler M; Bar M; Luria D; Ram E; Weizman A
Int J Oncol; 2008 Aug; 33(2):277-86. PubMed ID: 18636148
[TBL] [Abstract][Full Text] [Related]
31. Bioassays for anticancer activities.
McCauley J; Zivanovic A; Skropeta D
Methods Mol Biol; 2013; 1055():191-205. PubMed ID: 23963912
[TBL] [Abstract][Full Text] [Related]
32. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity.
Jung DJ; Shin TH; Kim M; Sung CO; Jang SJ; Jeong GS
Lab Chip; 2019 Sep; 19(17):2854-2865. PubMed ID: 31367720
[TBL] [Abstract][Full Text] [Related]
33. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
34. Antitumor components from Naematoloma fasciculare.
Yan D; Bao HY; Bau T; Li Y; Kim YH
J Microbiol Biotechnol; 2009 Oct; 19(10):1135-8. PubMed ID: 19884770
[TBL] [Abstract][Full Text] [Related]
35. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
[TBL] [Abstract][Full Text] [Related]
36. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
37. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells.
Hasan MN; Choudhry H; Razvi SS; Moselhy SS; Kumosani TA; Zamzami MA; Omran Z; Halwani MA; Al-Babili S; Abualnaja KO; Al-Malki AL; Alhosin M; Asami T
Bioorg Med Chem Lett; 2018 Apr; 28(6):1077-1083. PubMed ID: 29456109
[TBL] [Abstract][Full Text] [Related]
38. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
40. The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway.
Chen YJ; Chen HP; Cheng YJ; Lin YH; Liu KW; Chen YJ; Hou MF; Wu YC; Lee YC; Yuan SS
Life Sci; 2013 Jun; 92(22):1081-92. PubMed ID: 23624232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
